Skip to main content

Table 2 Univariate and multivariate analysis with respect to overall survival in 190 triple-negative breast cancers

From: Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67

 

Univarite analysis

Multivariate analysis

Parameters

Odds ratio

95% CI

P-value

Odds ratio

95% CI

P-value

Regimen

Anthracyclin-base vs 5FU-base

0.38

0.13 to 1.08

0.068

0.46

0.15 to 1.38

0.164

E-cadherin

      

Negative vs Positive

0.25

0.09 to 0.72

0.010

0.26

0.09 to 0.76

0.013

Ki67

      

Negative vs Positive

2.38

1.14 to 4.99

0.022

2.11

0.96 to 4.63

0.062

E-cadherin (-) and Ki67 (+)

      

Negative vs Positive

3.03

1.54 to 5.98

0.001

2.78

1.38 to 5.60

0.004

p53

      

Negative vs Positive

1.60

0.75 to 3.42

0.229

1.13

0.51 to 2.52

0.758

Stage

      

1 vs 2, 3, 4

2.54

1.04 to 6.22

0.041

0.30

0.05 to 2.00

0.214

Tumor size

      

≤ 2 cm vs > 2 cm

2.46

1.11 to 5.45

0.027

3.25

0.75 to 14.15

0.116

Lymph node status

      

N0 vs N1, N2, N3

3.40

1.68 to 6.91

0.001

3.46

1.38 to 8.66

0.008

Lymph-vascular invasion

      

Negative vs Positive

1.84

0.94 to 3.58

0.074

1.36

0.68 to 2.74

0.390

Nuclear grade

      

1, 2, vs 3

2.36

1.07 to 5.21

0.034

1.93

0.58 to 6.39

0.282